Patent Number: 6,165,460

Title: Generation of immune responses to prostate-specific antigen (PSA)

Abstract: We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.

Inventors: Schlom; Jeffrey (Potomac, MD), Panicali; Dennis L. (Acton, MA)

Assignee: Therion Biologics Corporation

International Classification: C12N 9/64 (20060101); A61K 39/00 (20060101); A01N 063/00 (); C12N 015/63 (); A61K 035/12 (); A61K 048/00 ()

Expiration Date: 12/26/2017